drugset / Trial / NCT02957396

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

NCT02957396

Phase 1 Completed 16 enrolled Bayer
RandomizedCrossoverOpen-labelOther

Summary

Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a novel liquid formulation for the treatment of children in comparison to the adult tablet formulation.

Timeline

Start
2016-11-17
Primary completion
2017-01-13
Completion
2017-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Finerenone Small molecule 20 mg Oral

Indications

No indication recorded.